NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

Violeta Serra, Ben Markman, Maurizio Scaltriti, +12

Cancer Research

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Lawrence Fong, Andrew Hotson, John D. Powderly, +30

Cancer Discovery

Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers

Oliver Klein, Damien Kee, Adnan Nagrial, +10

JAMA Oncology

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Nicolas Girard, Jair Bar, Pilar Garrido, +20

Journal of Thoracic Oncology

Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers

Oliver Klein, Damien Kee, Ben Markman, +11

Clinical Cancer Research

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial

Derek J. Jonker, Louise Nott, Takayuki Yoshino, +20

˜The œLancet. Gastroenterology & hepatology

Gastrointestinal OncologyMedicineRandomised Phase 3PharmacologyGastroenterology +5

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

Jayesh Desai, Sanjeev Deva, Jong Seok Lee, +22

Journal for ImmunoTherapy of Cancer

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial

Michael Friedländer, Tarek Meniawy, Ben Markman, +10

The Lancet Oncology

MedicinePharmacologyAdvanced Solid TumoursDose-escalation StagePharmacotherapy +4

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Jayesh Desai, Hui Gan, Catherine Barrow, +24

Journal of Clinical Oncology

A gut microbial signature for combination immune checkpoint blockade across cancer types

Ashray Gunjur, Yan Shao, Timothy Rozday, +15

Nature Medicine